Fifth Third Wealth Advisors LLC Trims Stake in Edwards Lifesciences Corporation $EW

Fifth Third Wealth Advisors LLC reduced its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 5.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,409 shares of the medical research company’s stock after selling 287 shares during the period. Fifth Third Wealth Advisors LLC’s holdings in Edwards Lifesciences were worth $423,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the company. Natural Investments LLC grew its position in shares of Edwards Lifesciences by 3.2% during the 2nd quarter. Natural Investments LLC now owns 5,097 shares of the medical research company’s stock valued at $398,000 after purchasing an additional 156 shares in the last quarter. Fulcrum Capital LLC grew its position in shares of Edwards Lifesciences by 3.8% during the 2nd quarter. Fulcrum Capital LLC now owns 131,109 shares of the medical research company’s stock valued at $10,254,000 after purchasing an additional 4,842 shares in the last quarter. Trust Co. of Toledo NA OH purchased a new position in shares of Edwards Lifesciences during the 2nd quarter valued at $153,000. Aberdeen Group plc grew its position in shares of Edwards Lifesciences by 10.1% during the 2nd quarter. Aberdeen Group plc now owns 522,175 shares of the medical research company’s stock valued at $40,839,000 after purchasing an additional 47,872 shares in the last quarter. Finally, PDS Planning Inc purchased a new position in shares of Edwards Lifesciences during the 2nd quarter valued at $212,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on EW shares. Daiwa America upgraded shares of Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 29th. Royal Bank Of Canada upped their target price on shares of Edwards Lifesciences from $85.00 to $89.00 and gave the stock an “outperform” rating in a research report on Friday, July 25th. Mizuho upped their target price on shares of Edwards Lifesciences from $87.00 to $95.00 and gave the stock an “outperform” rating in a research report on Friday, July 25th. JPMorgan Chase & Co. upped their target price on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the stock a “neutral” rating in a research report on Friday, July 25th. Finally, Barclays upped their target price on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock an “overweight” rating in a research report on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $87.06.

Edwards Lifesciences Stock Performance

NYSE EW opened at $74.02 on Monday. The company has a 50-day simple moving average of $78.09 and a two-hundred day simple moving average of $76.17. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12-month low of $64.89 and a 12-month high of $83.00. The firm has a market cap of $43.46 billion, a price-to-earnings ratio of 10.65, a PEG ratio of 3.55 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same period in the prior year, the business posted $0.70 earnings per share. The company’s revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, equities analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Activity

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of the company’s stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the sale, the vice president directly owned 22,002 shares in the company, valued at $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the company’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.